scholarly journals Awareness and knowledge of Human Papillomavirus ( HPV ), HPV ‐related cancers, and HPV vaccines in an uninsured adult clinic population

2016 ◽  
Vol 5 (11) ◽  
pp. 3346-3352 ◽  
Author(s):  
Carmen Radecki Breitkopf ◽  
Lila J. Finney Rutten ◽  
Victoria Findley ◽  
Debra J. Jacobson ◽  
Patrick M. Wilson ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccines ◽  
Clinic Population

Development of Human Papillomavirus (HPV) Vaccines: A Review of Literature and Clinical Update

2016 ◽  
Vol 11 (4) ◽  
pp. 284-289 ◽  
Author(s):  
Vikrant Chadrakant Sangar ◽  
Balasaheb Ghongane ◽  
Gaurav Mathur
Keyword(s):  
Human Papillomavirus ◽  
Review Of Literature ◽  
Hpv Vaccines

Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs

2019 ◽  
Vol 29 (8) ◽  
pp. 1317-1326 ◽  
Author(s):  
Raúl Murillo ◽  
Camila Ordóñez- Reyes
Keyword(s):  
Cervical Cancer ◽  
Clinical Trials ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Population Based ◽  
Immunization Programs ◽  
Hpv Vaccines ◽  
Middle Income ◽  
Middle Income Countries

Cervical cancer incidence and mortality have decreased in high-income countries, but low- and middle-income countries continue to bear a significant burden from the disease. Human papillomavirus (HPV) vaccines are a promising alternative for disease control; however, their introduction is slow in settings with greater need. We conducted a review of HPV vaccine efficacy and effectiveness reported in clinical trials and population-based studies. Efficacy of HPV vaccines is close to 100% when using a three-dose schedule in HPV-negative young women (<25 years old) for protection against persistent infection and HPV vaccine-type associated pre-cancerous lesions. Furthermore, sustained protection for up to 12 years of follow-up has been demonstrated; cross-protection against non-vaccine types is particularly observed for the bivalent vaccine, and preliminary data regarding impact on invasive cancer have emerged. Given its lower efficacy, catch-up vaccination beyond 19 years of age and proposals for vaccinating adult women deserve careful evaluation in accurately designed studies and economic analyses. Despite positive results regarding immunogenicity and post-hoc analysis for cervical intra-epithelial neoplasia in clinical trials, population-based data for prime and booster two-dose schedules are not available. Evaluation of vaccine safety from surveillance systems in immunization programs that have already distributed more than 270 million doses found no association of HPV vaccination with serious side effects. The introduction of HPV vaccination in national immunization programs remains the main challenge in tackling the burden of cervical cancer (up to 2018, only 89 countries have introduced vaccination worldwide, and most of these are high-income countries). Access models and technical capacity require further development to help low- and middle-income countries to increase the pace of vaccine delivery. Alternative approaches such as one-dose schedules and vaccination at younger ages may help reduce the programmatic and economic challenges to adolescent vaccination.

scholarly journals Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines

2005 ◽  
Vol 192 (7) ◽  
pp. 1158-1165 ◽  
Author(s):  
Fabián Méndez ◽  
Nubia Muñoz ◽  
Héctor Posso ◽  
Mónica Molano ◽  
Victor Moreno ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccines ◽  
Hpv Types

Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 383 ◽  
Author(s):  
Margaret E. Heffernan ◽  
Suzanne M. Garland ◽  
Mark A. Kane
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hpv Vaccination ◽  
Primary Hepatocellular Carcinoma ◽  
Health Providers ◽  
Hpv Vaccines ◽  
B Virus ◽  
Global Reduction

Background: Worldwide, prophylactic vaccines against two major human cancers are now commercially available: hepatitis B virus (HBV) vaccines (first licensed in 1982) against primary hepatocellular carcinoma and human papillomavirus (HPV) vaccines (first licensed 2006) against cervical cancer. Initial implementation strategies for HBV vaccination were not successful in preventing disease in the community: it took 15 years for significant global reduction in the burden of this disease. Methods: We compare and contrast HBV vaccine experiences to challenges for successful global HPV vaccination strategies, and make recommendations accordingly. Results: Lessons from HBV immunisation for successful outcomes with HPV immunisation showed that several factors need to be met: (i) the engagement of key stakeholders in all aspects of planning and delivery of HPV vaccine strategies; (ii) understanding the specific characteristics of targeted population groups; (iii) global cooperation and support with WHO recommendations; (iv) Government supported mass immunization programs and cooperation between public and private entities; (v) affordable HPV vaccines for some regions; (vi) culturally appropriate and diverse public education programs in targeted health promotion strategies; (vii) pro-active health providers and parents in encouraging adolescents to undertake HPV vaccination; and (vii) eventual immunisation of infants. Conclusions: The key to success will be affordable, readily deliverable HPV vaccines to young girls as universal campaigns.

Sign in / Sign up

Export Citation Format

Share Document